Max Robotics — Global Service Robot Directory + US Certification

About

Dr. Chan Min Jung is a pioneering head and neck surgeon whose research focuses on advancing minimally invasive surgical treatments for oropharyngeal and hypopharyngeal cancers. Her major contributions center on the integration of transoral robotic surgery (TORS) with neoadjuvant chemotherapy and customized adjuvant therapy, particularly for patients with advanced-stage disease. In her landmark 2017 study on TORS for hypopharyngeal cancer, she demonstrated that the approach yields favorable long-term oncological outcomes while preserving swallowing and speech function—a critical advance for quality of life. That work has garnered 48 citations, reflecting its influence on surgical practice. Her subsequent clinical trial for T3/T4 oropharyngeal cancer, cited 27 times, established a novel paradigm combining neoadjuvant chemotherapy with TORS and personalized adjuvant protocols, challenging traditional chemoradiation standards. Dr. Jung’s research has been instrumental in expanding the indications for robotic surgery to more complex tumors, reducing the need for morbid open procedures. Her work continues to shape evidence-based guidelines for organ-preserving strategies in head and neck oncology, making her a leading voice in the field.